Clinical Study of Intrapleural Injection of Lobaplatin Combined with Recombinant Human Endostatin (endostar) in Treatment of Lung Cancer with Malignant Pleural Effusion

Abstract

Abstract:

Objective: To study the efficacy and safety of intrapleural injection of lobaplatin combined with endostar in treatment of
lung cancer with malignant pleural effusion. Methods: Sixty-three patients diagnosed lung cancer with malignant pleural effusion
were treated by the way of intrapleural injection. The subjects were divided into two groups: 32 cases were injected lobaplatin and
endostar (A group), 31 cases were injected cisplatin and endostar (B group). The clinical efficacy, quality of life and toxic reaction
were compared between groups. Results: The clinical efficacy and quality of life were not significantly different between two groups
(P>0.05). The incidences of WBC reduction, hypohemia, sicchasia and vomit were significant higher in B group than that in A (P<0.05). Conclusion: Lobaplatin combined with endostar therapy showed almost the same clincal efficacy compared to the therapy of
cisplatin combined with endostar in treatment of lung cancer with malignant pleural effusion, but with less side effect.

Key words: lobaplatin, endostar, lung cancer, malignant pleural effusion

CLC Number:

R734.2

CAO Yu, ZHAO Guang-Qiang, HUANG Yun-Chao. Clinical Study of Intrapleural Injection of Lobaplatin Combined with Recombinant Human Endostatin (endostar) in Treatment of Lung Cancer with Malignant Pleural Effusion[J]. J4, 2012, 11(12): 41-43.

References

〔1〕童志伟，谷铣之.临床肺病学〔M〕.北京：人民卫生出版社，
2002：1578-1586.
〔2〕Mountain CF. Revisions in the international system for
staging lung cancer〔J〕.Chest，1997，111（6）：1710-1717.
〔3〕Frank C，Detterbeck，Daniel J，et al.The New Lung Cancer
Staging System〔J〕.Chest，2009，136（1）：259-273.
〔4〕Hong JW，Choi GJ.Ahmed valve implantation for refractory
glaucoma following pars plana vitrectomy〔J〕.Korean J
Ophthalmol，2005，19（3）：293-296.
〔5〕Grove CS，Lee YC.Vascular endothelial growth factor：the
key mediator in pleural effusion formation〔J〕.CurrOpin
Pulm Med，2002，8（4）：294.
〔6〕刘淑真，于国华.恩度联合PDD治疗恶性胸腔积液的疗效
分析〔J〕.潍坊医学院学报，2009，31（3）：225-226.
〔7〕刘维，哈敏文，殷南昌，等. 恩度联合PDD胸腔内注射治疗
非小细胞肺癌恶性胸腔积液临床研究〔J〕.山东医药，
2010，50（8）：79-80.
〔8〕Mc keage MJ.Lobaplatin：a new antitumour platimum drug
〔J〕.Expert Opin Investig Drugs，2001，10（1）：119-128.
〔9〕刘鲁平，张玉星.紫杉醇联合洛铂或顺铂治疗晚期非小细
胞肺癌48例比较〔J〕.现代肿瘤学杂志，2011，19（1）：78-79.
〔10〕曾洪生，郭其森，傅玲.吉西他滨联合洛铂治疗晚期非小
细胞肺癌疗效分析〔J〕.山东医药，2011，51（19）：29-31.
〔11〕董岩，李颖.洛铂与顺铂联合培美曲塞一线治疗晚期肺
腺癌的临床观察〔J〕.医学与哲学，2011，32（10）：27-28.
〔12〕楼丽广.洛铂扩大适应症（非小细胞肺癌）临床前主要药
效学研究〔悦〕/丁键.2009医学前沿论坛暨第十一届全
国肿癌药理与化学会议论文集.上海：中国科学出版
社，2009：162.
〔13〕Alami NZ，Li ZH，Engel JG，et al.Comparative preclinical
anti-proliferation activity of lobaplatin vs cisplatin，
carboplatin，oxalilatin and satraplatin in breast and
ovarian cancers〔C〕.Proceeding of the 98th AACR Annual
Meeting. Los Angels：CA，2007：a4780.
〔14〕史健，王桂英，单保恩，等. 洛铂术前化疗后乳腺癌组织
中Syk表达及其分子机制的研究〔J〕.中国老年学杂志，
2008，28（7）：636-640.
〔15〕陈彦平，史健，杨会钗，等. 术前洛铂化疗对口腔鳞癌抑
癌基因PTEN表达的影响〔J〕.实用口腔医学杂志，2008，
24（6）：893-897.
〔16〕史健，袁志芳，刘伟娜，等. 国产注射用洛铂在恶性肿瘤
患者体内药动学的研究〔J〕.中国药学杂志，2007，42
（24）：1888-1891.